News

Good news for more than 2 million Australians who suffer from asthma, with scientists a step closer to a cure after ground-breaking research at one of our universities. Karen O'Sullivan...

Read More

CPS Capital CEO, Jason Peterson advised current and potential investors that as a major shareholder of Cynata Therapeutics Ltd (“CYP”), he has recently been meeting management, organising a marketing strategy...

Read More

Sistemic Ltd. and Cynata Therapeutics Limited (ASX:CYP) announced today that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its...

Read More

Cynata Therapeutics Limited CYP-AU: Price: A$0.30; Market Cap (MM): A$22 Rating: Buy; Price Target: A$1.00 Raghuram Selvaraju, Ph.D., Senior Biotechnology Analyst MHRA Favorable Advice Received; Proceeding to Clinical Testing Click here for complete report and disclosures Regulatory...

Read More